ArticleThe oncologist2013
Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study.
Article in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis.JAMA ophthalmology · 2021Pooled it
- Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Internal and emergency medicine · 2016Pooled it
- Trastuzumab-containing regimens for metastatic breast cancer.The Cochrane database of systematic reviews · 2014Pooled it
- Risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.Frontiers in oncology · 2026Article
- Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort study.BMJ oncology · 2023Article
- The Association between Vision Impairment and Depression: A Systematic Review of Population-Based Studies.Journal of clinical medicine · 2022Review
- Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan.ESC heart failure · 2021Article
- Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.JAMIA open · 2019Article
- Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: A pilot study.Medicine · 2019Article
- 3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis.Translational oncology · 2018Article
- Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Oxidative medicine and cellular longevity · 2018Review
- Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.Journal of breast cancer · 2017Article
- Observational
- Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion.Case reports in cardiology · 2017Article
- Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Targeted oncology · 2016Review
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer.Journal of geriatric cardiology : JGC · 2016Review
- Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.Drugs & aging · 2015Article
- Infracentimetric HER-2 positive breast tumours-review of the literature.Ecancermedicalscience · 2015Review
- Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.The oncologist · 2014Article
- An update on cardio-oncology.Trends in cardiovascular medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcerns have been raised about the cardiac safety profile of trastuzumab for the adjuvant treatment of early stage breast cancer in clinical practice. We assessed trastuzumab-related cardiotoxicity and its predictors in a large cohort of Italian women.
methodsThrough a record linkage between four regional health care databases, we identified the rate of severe cardiac adverse events among women treated with trastuzumab for early breast cancer in Lombardy. The cumulative risk of cardiotoxicity was estimated using the Kaplan-Meier method, and independent predictors were assessed using the Cox model.
resultsOf 2,046 trastuzumab users, 53 (2.6%) experienced at least one hospitalization for a cardiac event, and there were two cardiac deaths. The cumulative risk of cardiotoxicity increased up to 2 years after starting treatment, reaching a plateau at 2.8%. The risk was low (0.2%) among young women, whereas the incidence was approximately 10% in women aged ≥70 years, irrespective of cardiovascular risk factors. Age and history of cardiac disease were strong predictors of cardiotoxicity, with a hazard ratio of 11.3 (95% confidence interval [CI]: 3.5-36.6) for women aged ≥70 years as compared with those <50 years of age. Hazard ratio was 4.4 (95% CI: 2.1-9.5) for women with a history of cardiac disease compared with those without a history of cardiac disease.
conclusionsCardiotoxicity of trastuzumab varies considerably across subgroups of patients. The long-term safety profile was less favorable than in the largest clinical trial. Strategies to reduce cardiotoxicity in high-risk women should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.